CTA Treatment Regimen Chart for Esophageal and EGJ Cancers Updated

Share this content:
CTA has updated its treatment regimen chart for the treatment of esophageal and esophagogastric junction cancers.
CTA has updated its treatment regimen chart for the treatment of esophageal and esophagogastric junction cancers.

Cancer Therapy Advisor has updated its treatment regimen chart for the treatment of esophageal and esophagogastric junction cancers to reflect the most recent changes put forth by Version 2.2016 of the National Comprehensive Cancer Network (NCCN) Guidelines for Esophageal and Esophagogastric Junction Cancers.

Key updates from Version 2.2016 and Version 1.2016 for the systemic treatment of metastatic or locally advanced esophageal and esophagogastric junction cancers include:

  1. DCF (docetaxel, cisplatin, and fluorouracil) (Category 1) was removed as a preferred treatment option as first-line therapy.
  2. ECF (epirubicin, cisplatin, and fluorouracil) (Category 1) and ECF modifications (Category 1) were removed from the list of preferred regimens for first-line therapy and added to the list of other regimens.
  3. Docetaxel and irinotecan was removed as an option for first-line therapy.
  4. Alternative regimens for consideration, including mitomycin plus irinotecan or fluorouracil, were removed.


Reference

  1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Esophageal and Esophagogastric Junction Cancers. V 2.2016. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Updated July 7, 2016. Accessed September 20, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters